Zetia Controversy
Links shared publicly online about this topic
Premature release of trial data
theheart.org — “Very little about ezetimibe followed the usual course, particularly the release of clinical-trial data outside of traditional, large-scale cardiology meetings or peer-reviewed journals. In a special report, Drs Robert Califf, Robert Harrington, and Michael Blazing discuss new recommendations that will help balance the demands from Wall Street, the sponsor, and clinical investigators.” View full resource at theheart.org
Most Recently Shared on August 13, 2009 at 4:46 pm By:
heartwire: Ezetimibe fallout: Experts discuss the premature release of clinical-trial data http://bit.ly/XP6Qk
Merck/Schering Plough reaches settlement with states
theheart.org — “The companies have agreed to reimburse 35 states and the District of Columbia to the tune of $5.4 million, part of a settlement stemming from investigations into how they marketed Vytorin and Zetia before announcing the ENHANCE trial's controversial results.” View full resource at theheart.org
Most Recently Shared on July 21, 2009 at 6:47 pm By:
heartwire: Merck/Schering-Plough reach ezetimibe settlement http://bit.ly/JVIom
Can I Stop Taking Vytorin Without Bad Side Effects? - Health Advice (usnews.com)
health.usnews.com — “Yes, many physicians have switched patients without harm.” View full resource at health.usnews.com
Most Recently Shared on January 14, 2010 at 10:17 pm By:
HealthIT Policy Health News and Health IT
Can I Stop Taking Vytorin Without Bad Side Effects?: Yes, many physicians have switched patients without harm. http://bit.ly/8qvsYY
Abbott’s Ticking Time Bomb - Matthew Herper - The Medicine Show - Forbes
blogs.forbes.com — “On Thursday, Abbott Laboratories' heart drugs Tricor and TriLipix will face an FDA advisory panel which will examine how the medicines should be used given the lack of evidence for them. Although this controversy has flown under the radar compared to the one that hit Merck's Zetia a few years [...]” View full resource at blogs.forbes.com
Most Recently Shared on May 17, 2011 at 2:45 pm By:
Drugs and Devices OW OW Health
Abbott's Ticking Time Bomb: Controversy is brewing on Abbott's triglyceride lowering drug. http://onforb.es/lsZomE #drug
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Shelley Wood
Managing editor for heartwire on theheart.org--the most authoritative, balanced, and insightful cardiovascular disease news online. http://is.gd/nHJ4
-
Shelley Wood
Managing editor for heartwire on theheart.org--the most authoritative, balanced, and insightful cardiovascular disease news online. http://is.gd/nHJ4
-
HealthIT Policy
Health IT Policy News and Updates
Advertisement
